Rep. Slaughter Offers Bill To Tighten ‘Ethics Loopholes’ On Congressional Stock Trading
Controversial purchases of stock in an Australian drug company by Reps. Chris Collins (R-N.Y.) and Tom Price (R-Ga.), now the secretary of the Department of Health and Human Services, prompted the move, Rep. Louise Slaughter (D-N.Y.) says. Also on Capitol Hill, Democrats press a bill that would ban "conversion therapy" treatments to change a person's sexual orientation.
The Washington Post:
Lawmakers’ Questionable Stock Trades Prompt New Bill
Rep. Louise M. Slaughter introduced a bill Friday to close “ethics loopholes” in a five-year-old law that has failed to stop members of Congress from taking advantage of exclusive stock deals that are not available to the general public. Slaughter (D-N.Y.), a co-author of the 2012 Stock Act, said she decided that amendments to the law are needed because of controversial, discounted stock purchases that were made by Reps. Chris Collins (R-N.Y.) and Tom Price (R-Ga.), now the secretary of health and human services, in 2015 and 2016. (Kindy, 4/28)
The Washington Post:
The Therapeutic Fraud Prevention Act Of 2017 Was Introduced By Democrats In Congress
Democratic lawmakers this week introduced a bill that would ban the practice of “conversion therapy,” treatments that historically have targeted the LGBT community and claim to be able to change a person’s sexual orientation or gender identity. The Therapeutic Fraud Prevention Act of 2017 was introduced Tuesday by Rep. Ted Lieu (D-Calif.), along with Sens. Patty Murray (D-Wash.) and Cory Booker (D-N.J.). About 70 other members of Congress, all Democrats, have said they support the bill, which would allow the Federal Trade Commission to classify conversion therapy and its practitioners as fraudulent. (Wang, 4/27)
